Devalingam Mahalingam
Overview
Explore the profile of Devalingam Mahalingam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
2711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demir T, Moloney C, Mahalingam D
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075563
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a poor prognosis. Currently, chemotherapy is the only option for most patients with advanced-stage PDAC. Further, conventional immunotherapies and targeted therapies...
2.
Goldman J, Bueno A, Dooms C, Jhaveri K, de Miguel M, Piha-Paul S, et al.
Clin Lung Cancer
. 2025 Jan;
PMID: 39828466
Background: Activating mutations in the epidermal growth factor receptor (EGFR) gene occur in 7% to 23% of patients with non-small-cell lung cancer (NSCLC). A small proportion of these (3-5%) are...
3.
Mahalingam D, Owonikoko T, Delpassand E, Mulcahy M, Kalyan A, Ulahannan S, et al.
Cancer
. 2025 Jan;
131(1):e35680.
PMID: 39748726
Background: Yttrium-90 FF-21101 (Y-FF-21101) is a radiopharmaceutical that targets P-cadherin as a therapy against solid tumors. A previously reported, first-in-human study determined that a dose of 25 mCi/m was safe,...
4.
Maldonado E, Rathmell W, Shapiro G, Takebe N, Rodon J, Mahalingam D, et al.
Cancer Res Commun
. 2024 Jun;
4(7):1793-1801.
PMID: 38920407
Significance: WEE1 inhibition with adavosertib monotherapy demonstrated limited clinical activity in patients with SETD2-altered solid tumors despite compelling preclinical data indicating a synthetic lethal effect, which did not translate into...
5.
Vallejo S, Mahalingam D, Court C, Ketchum N, Gelfond J, Michalek J, et al.
J Geriatr Oncol
. 2024 Jun;
15(7):101816.
PMID: 38902147
No abstract available.
6.
Chen J, Vincent M, Shepard D, Peereboom D, Mahalingam D, Battiste J, et al.
Commun Med (Lond)
. 2024 May;
4(1):95.
PMID: 38773224
Background: Preclinical studies have demonstrated that VT1021, a first-in-class therapeutic agent, inhibits tumor growth via stimulation of thrombospondin-1 (TSP-1) and reprograms the tumor microenvironment. We recently reported data from the...
7.
Demir T, Moloney C, Mahalingam D
Crit Rev Oncol Hematol
. 2024 May;
199:104388.
PMID: 38754771
In the last decade, targeted therapies have shown rapid advancement in biliary tract cancer (BTC). Today, many targeted agents are available and under investigation for patients with BTC. More recently,...
8.
Fontana E, Rosen E, Lee E, Hojgaard M, Mettu N, Lheureux S, et al.
J Natl Cancer Inst
. 2024 May;
116(9):1439-1449.
PMID: 38710487
Background: Camonsertib is a selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with demonstrated efficacy in tumors with DNA damage response gene deficiencies. On-target anemia is the main...
9.
Janczewski L, Joung R, Borhani A, Lewandowski R, Velichko Y, Mulcahy M, et al.
HPB (Oxford)
. 2024 Feb;
26(5):656-663.
PMID: 38383208
Background: Hepatic artery infusion (HAI) is less frequently used in the adjuvant setting for resectable colorectal liver metastasis (CRLM) due to concerns regarding toxicity. Our objective was to evaluate the...
10.
Mahalingam D, Harb W, Patnaik A, Bullock A, Watnick R, Vincent M, et al.
Commun Med (Lond)
. 2024 Jan;
4(1):10.
PMID: 38218979
Background: VT1021 is a cyclic peptide that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). TSP-1 reprograms the TME via binding...